Clinical-stage biotechnology company Allon Therapeutics Inc (NPC.TO: Quote) Wednesday announced that the company has been granted a U.S Patent for its neuroprotective technology platform which is used in the treatment of peripheral neuropathy.
The company further added that the U.S Patent includes lead drug candidate, davunetide, and pipeline product AL-309 as treatments for peripheral neuropathy caused by anti-cancer drugs.
Dr. Alistair Stewart, Allon's Vice President of Commercial Research, said :" The granting of this US patent shows Allon's commitment to building comprehensive intellectual property covering its technology in a variety of settings, including disease prevention,"
Click here to receive FREE breaking news email alerts for Allon Therapeutics Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com